A comparison of the reactivating and therapeutic efficacy of newly developed bispyridinium oximes (K250, K251) with commonly used oximes against tabun in rats and mice

Abstrakt

The reactivating and therapeutic potency of both newly developed oximes (K250, K251) does not prevail the effectiveness of currently available oximes and, therefore, they are not suitable for the replacement of commonly used oximes by them for the treatment of acute tabun poisoning.